摘要
目的分析表柔比星联合紫杉醇化疗的胃癌根治术患者血清HSP90α、CYFR211水平及预后影响因素。方法选择胃癌根治术的患者96例,均采用表柔比星联合紫杉醇经动脉介入化疗。比较治疗前、治疗6周后、治疗12周后患者血清HSP90α、CYFR211水平。对患者随访2年,统计患者无进展生存时间(PFS)和总生存时间(OS),根据实体肿瘤WHO客观评价标准对患者预后进行评估,分为预后不良组和预后良好组,并通过单因素分析和多因素logistic回归分析影响胃癌根治术患者预后的危险因素。结果治疗6周后,2组患者血清HSP90α、CYFR211水平较治疗前低(P<0.05),治疗12周后,2组患者血清HSP90α、CYFR211水平较治疗前及治疗6周后低(P<0.05)。患者6个月、1年、2年无进展生存率分别为58.3%、30.2%、20.2%,6个月、1年、2年总生存率分别为81.2%、63.5%、32.6%,中位PFS和OS分别为10个月、16个月。单因素分析显示:胃癌根治术患者的预后与性别、体质指数、手术出血量、手术方式、术后是否出现严重不良反应、胃癌发生部位无关(P>0.05),而与年龄、肿瘤直径、手术时间、胃切除范围、TNM分期、肿瘤分化程度有关(P<0.05);多因素分析显示,年龄、肿瘤直径、胃切除范围、手术时间、TNM分期、肿瘤分化程度是影响胃癌根治术患者预后不良的独立危险因素(P<0.05)。结论表柔比星联合紫杉醇经动脉介入化疗治疗胃癌根治术患者,可以降低血清HSP90α、CYFR211水平,疗效尚可。年龄、肿瘤直径、胃切除范围、手术时间、TNM分期、肿瘤分化程度是胃癌根治术患者预后的独立影响因素。
Objective To analyze serum HSP90αand CYFR211 levels and prognostic factors of patients underwent radical gastrectomy with epirubicin combined with paclitaxel chemotherapy.Methods 96 patients who underwent radical gastrectomy for gastric cancer were selected and treated with epirubicin combined with paclitaxel through arterial interventional chemotherapy.The serum HSP90αand CYFR211 levels were compared before treatment,after 6 weeks of treatment,and after 12 weeks of treatment.The patients were followed up for 2 years,and the progression-free survival(PFS)and overall survival(OS)were counted.The prognosis of patients was evaluated according to the WHO objective evaluation criteria for solid tumors,and they were grouped into a poor prognosis group and a good prognosis group.Univariate analysis and multivariate logistic regression were used to analyze the risk factors affecting the prognosis of patients with radical gastrectomy for gastric cancer.Results After 6 weeks of treatment,the levels of serum HSP90αand CYFR211 in the 2 groups were lower than those before treatment(P<0.05),and after 12 weeks of treatment,the levels of serum HSP90αand CYFR211 in the 2 groups were lower than those before treatment and after 6 weeks of treatment(P<0.05);the 6-month,1-and 2-year progression-free survival rates were 58.3%,30.2%,and 20.2%,respectively,and the 6-month,1-and 2-year overall survival rates were 81.2%,63.5%,and 32.6%,respectively,the median PFS and OS were 10 months and 16 months,respectively;the prognosis of patients undergoing radical gastrectomy for gastric cancer was not related to gender,body mass index,surgical blood loss,surgical method,postoperative serious adverse reactions,and the location of gastric cancer(P>0.05),it was related to age,tumor diameter,operation time,extent of gastrectomy,TNM stage,and tumor differentiation(P<0.05);age,tumor diameter,extent of gastrectomy,operation time,TNM stage,and tumor differentiation were independent risk factors for poor prognosis in patients with radical gastrectomy(
作者
刘要先
王海增
刘刚
邓飞
LIU Yaoxian;WANG Haizeng;LIU Gang(Luohe First People's Hospital(Luohe Central Hospital),Luohe,462000)
出处
《实用癌症杂志》
2024年第4期636-640,共5页
The Practical Journal of Cancer
关键词
胃癌根治术
表柔比星
紫杉醇
经动脉介入化疗
预后
Radical gastrectomy
Epirubicin
Paclitaxel
Transarterial chemotherapy
Prognosis
